Company intelligence / Profile preview
Design Therapeutics
Carlsbad, California, United Statesdesigntx.com ↗
- Ownership
- Public · DSGN
- Employees
- ~100
- Development stage
- Phase 1
01
Overview
Design Therapeutics has advanced its lead program DT‑216P2 for Friedreich ataxia into a Phase 1 single ascending dose trial in healthy volunteers; patient dosing expected mid‑2025. Its second program DT‑168 for FECD completed Phase 1 healthy volunteer dosing with data expected first half of 2025. A development candidate selection for DM1 is anticipated in 2025. The company reports preclinical progress on additional programs and discovery efforts across multiple genetic diseases caused by nucleotide repeat expansions. Early clinical results have demonstrated target engagement and modulation after a single dose of their lead compound.
- Therapeutic areas
- OphthalmologyNeurology
- Modalities
- Small molecules (specifically GeneTAC® gene targeted chimera small molecules)
- Industry
- Biotech
02
Drug pipeline
8 assets7 more assets in the full pipeline.
Request access →03
Partnerships
No major pharma partnerships disclosed as of May 2025.
04
Financials
- Market cap
- $951.2M
- Total revenue
- $0
- Enterprise value
- $745.9M
Beyond the preview
Go deeper on Design Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Design Therapeutics.